Cytotoxicity of VEGF121/rGel on vascular endothelial cells resulting in inhibition of angiogenesis is mediated via VEGFR-2 by Mohamedali, Khalid A et al.
RESEARCH ARTICLE Open Access
Cytotoxicity of VEGF121/rGel on vascular
endothelial cells resulting in inhibition of
angiogenesis is mediated via VEGFR-2
Khalid A Mohamedali
1*, Sophia Ran
5, Candelaria Gomez-Manzano
2, Latha Ramdas
3, Jing Xu
2,8, Sehoon Kim
1,9,
Lawrence H Cheung
1, Walter N Hittelman
1, Wei Zhang
4, Johannes Waltenberger
6, Philip E Thorpe
7 and
Michael G Rosenblum
1
Abstract
Background: The fusion protein VEGF121/rGel composed of the growth factor VEGF121 and the plant toxin gelonin
targets the tumor neovasculature and exerts impressive anti-vascular effects. We have previously shown that
VEGF121/rGel is cytotoxic to endothelial cells overexpressing VEGFR-2 but not to endothelial cells overexpressing
VEGFR-1. In this study, we examined the basis for the specific toxicity of this construct and assessed its intracellular
effects in vitro and in vivo.
Methods: We investigated the binding, cytotoxicity and internalization profile of VEGF121/rGel on endothelial cells
expressing VEGFR-1 or VEGFR-2, identified its effects on angiogenesis models in vitro and ex vivo, and explored its
intracellular effects on a number of molecular pathways using microarray analysis.
Results: Incubation of PAE/VEGFR-2 and PAE/VEGFR-1 cells with
125I-VEGF121/rGel demonstrated binding specificity
that was competed with unlabeled VEGF121/rGel but not with unlabeled gelonin. Assessment of the effect of
VEGF121/rGel on blocking tube formation in vitro revealed a 100-fold difference in IC50 levels between PAE/VEGFR-2
(1 nM) and PAE/VEGFR-1 (100 nM) cells. VEGF121/rGel entered PAE/VEGFR-2 cells within one hour of treatment but
was not detected in PAE/VEGFR-1 cells up to 24 hours after treatment. In vascularization studies using chicken
chorioallantoic membranes, 1 nM VEGF121/rGel completely inhibited bFGF-stimulated neovascular growth. The
cytotoxic effects of VEGF121/rGel were not apoptotic since treated cells were TUNEL-negative with no evidence of
PARP cleavage or alteration in the protein levels of select apoptotic markers. Microarray analysis of VEGF121/rGel-
treated HUVECs revealed the upregulation of a unique “fingerprint” profile of 22 genes that control cell adhesion,
apoptosis, transcription regulation, chemotaxis, and inflammatory response.
Conclusions: Taken together, these data confirm the selectivity of VEGF121/rGel for VEGFR-2-overexpressing
endothelial cells and represent the first analysis of genes governing intoxication of mammalian endothelial cells by
a gelonin-based targeted therapeutic agent.
Background
Continuing investigations into the biology of tumor-
stromal interactions have identified a number of path-
ways and events critical to the development and
maintenance of tumors and their metastatic spread.
Tumor neovascularization is a critical, robust process
dependent on the interplay between numerous soluble
cytokines, growth factors and their receptors.
Targeted therapy focusing on the tumor neovasculari-
zation process appears to be a promising approach in
this regard [1]. The VEGF-A family of cytokines and
their cognate receptors have been identified as
key mediators of angiogenesis and endothelial cell
proliferation, migration and survival [2-6], and
play a central role in the organization of solid tumor
vasculature [7,8].
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two receptors designated VEGFR-1 (Flt-1/FLT-1) and
VEGFR-2 (Flk-1/KDR), both of which are over-expressed
on the endothelium of tumor vasculature but virtually
undetectable in the vascular endothelium of adjacent nor-
mal tissues. We have previously characterized a novel
fusion construct of VEGF121 and the plant toxin Gelonin
(rGel). Gelonin is a 28.5 kDa single-chain protein belong-
ing to the family of Type 1 plant Ribosome-Inactivating
Proteins (RIPs) that can hydrolyze the glycosidic bond of
a highly conserved adenosine residue in the largest RNA
in the 28S ribosome, resulting in irreversible inhibition of
protein synthesis. In vivo,V E G F 121/rGel targets and
destroys tumor neovasculature in solid tumors [9,10],
reduces breast cancer metastatic spread and dramatically
reduces neovascularization of pulmonary breast metas-
tases [11], prevents tumor growth in bone in osteolytic
and osteoblastic bone metastasis models [12,13], and
blocks retinal and choroidal neovascularization in studies
of experimental ocular neovascular disease [14]. The
binding of VEGF121/rGel to both VEGFR-1 and VEGFR-
2 has been demonstrated in vivo using non-invasive bio-
luminescence imaging (BLI), magnetic resonance imaging
(MRI) and positron-emission tomography (PET) [15].
Thus, VEGF121/rGel appears to be a promising candidate
for targeting its cognate receptors in various disease
states.
Interestingly, VEGF121/rGel demonstrates targeted
toxicity in vitro to endothelial cells which over-express
VEGFR-2 (IC50 = 0.5 - 1 nM) but not to cells which
over-express VEGFR-1 (IC50 = 300 nM) compared to
gelonin alone (IC50 = 300 nM) [10]. This is surprising
since VEGF121 binds to both receptors with affinity in
the picomolar range [16]. There are several possibilities
that may account for this difference in toxicity: (a) the
binding affinity of VEGF121/rGel to VEGFR-1 may be
reduced, (b) binding affinity is not affected but the rate
of internalization of VEGF121/rGel bound to VEGFR-1 is
reduced compared to VEGFR-2 and (c) different access
to the ribosomal machinery following cell entry due to
being trapped in the endosomal compartment. In addi-
tion, while the molecular effects of VEGF121-treatment
of endothelial cells have been studied [17], the effects of
VEGF121/ r G e lo ne n d o t h e l i a lc e lls have yet to be eluci-
dated. This information is critical in the context of in
vivo targeting because of the potential role that stimula-
tion by VEGF121 can have on cell survival and rGel-
mediated toxicity. For example, VEGF121 may activate
particular signal transduction pathways early in the pro-
cess that can result in increased toxicity of the rGel
component even prior to complete inhibition of protein
synthesis. The biochemical process of drug action, and
its off-target effects can best be studied under controlled
conditions in vitro.I nt h i sr e p o r t ,w ef o c u so n
understanding the mechanism of action of VEGF121/
rGel on endothelial cells by determining its binding pro-
file to VEGFR-1 and VEGFR-2, identifying its effects on
angiogenesis models in vitro and ex vivo,a n de x p l o r i n g
its intracellular effects on a number of molecular path-
ways using microarray analysis.
Methods
Cell Culture
Porcine aortic endothelial (PAE) cells transfected with
the human VEGFR-2 (PAE/VEGFR-2) or the human
VEGFR-1 (PAE/VEGFR-1) have been used as in vitro
models of angiogenesis [18]. The number of R-2 and R-
1 receptor sites on these cells lines have been previously
determined at 150,000 and 50,000 per cell, respectively
[19]. Human umbilical vein endothelial cells (HUVECs)
were maintained in EBM medium (Cambrex, East
Rutherford, NJ).
Purification of VEGF121/rGel
Construction and purification of VEGF121/rGel was
essentially as described [10]. VEGF121/rGel was concen-
trated and stored in sterile PBS at -20°C.
Western Blot Analysis
Whole cell extracts of HUVECs, PAE/VEGFR-2 and
PAE/VEGFR-1 cells were prepared as described [11].
Western blotting was performed using antibodies for
actin (loading control), VEGFR-2, p-VEGFR-2 (p-KDR),
E-selectin, and various apoptotis markers.
Cell Surface Binding of Radiolabeled VEGF121/rGel to PAE/
VEGFR-2 and PAE/VEGFR-1 cells
VEGF121/rGel was radiolabeled with 1mCi of NaI
125
using Chloramine T [20] for a specific activity of 602
Ci/mMol. Equivalent numbers of cells were grown over-
night in 24-well plates and cell surface binding assays
were performed as described previously [21]. Briefly,
non-specific binding sites were blocked for 30 minutes
with PBS/0.2% gelatin followed by incubation for 4
hours at 4°C with
125I-VEGF121/rGel (10 nM) in PBS/
0.2% gelatin solution. For competition experiments, cold
VEGF121/rGel or gelonin (400 nM) were pre-mixed with
125I-VEGF121/rGel. Cells were washed four times with
PBS/0.2% gelatin solution, detached and bound cpm was
measured.
Cytoxicity and Internalization of VEGF121/rGel and rGel
Cytotoxicity of VEGF121/rGel and rGel against log phase
PAE/VEGFR-2 cells was performed over 72 hours as
described for PAE/KDR and PAE/FLT-1 cells [10]. To
assess if the activity of VEGF121/rGel was affected by the
exposure time to endothelial cells, log-phase PAE/
VEGFR-2 cells were treated with VEGF121/rGel and
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varying time-points and replaced with fresh media. For
internalization, cells were treated with 4 μg/ml (48 nM)
VEGF121/rGel at the timepoints indicated, then washed
with Glycine buffer (500 mM NaCl, 0.1 M glycine, pH
2.5) to remove cell surface-bound VEGF121/rGel. Cells
were incubated with a rabbit anti-gelonin polyclonal
antibody (1:200) followed by a FITC-conjugated anti-
r a b b i ts e c o n d a r ya n t i b o d y( 1 : 8 0 ) .N u c l e iw e r es t a i n e d
with propidium iodide (1 μg/ml) in PBS. The slides
were mounted with DABCO reagent and visualized
under fluorescence (Nikon Eclipse TS1000) and confocal
(Zeiss LSM 510) microscopes.
TUNEL Assay
Log phase PAE/VEGFR-2 and PAE/VEGFR-1 cells (2000
cells/well) were treated with 1 nM VEGF121/rGel for 72,
48 and 24-hours. The cells were then processed and
analyzed for TUNEL as described by the manufacturer
of the reagent (Roche Diagnostics, Indianapolis, IN).
Endothelial Cell Tube Formation Assay
PAE/VEGFR-2 and PAE/VEGFR-1 cells plates on Matri-
gel were treated with 0.01 - 100 nM VEGF121/rGel or
rGel, in triplicate, for 24 h. Inhibition of tube formation
was assessed by counting the number of tubes formed
per well under bright field microscopy. The ability of
VEGF121/rGel to inhibit tube formation as a function of
incubation time before plating on Matrigel was studied
by incubating PAE/VEGFR-2 cells at the IC50 dose (1
nM) for different periods up to 24 h. Cells were
detached and plated in 96-well Matrigel-coated plates
under the conditions described above and the tubes in
each well were counted.
Angiogenesis Assessment in Chicken Chorioallantoic
Membranes
Chorioallantoic membrane (CAM) experiments using
fertilized chicken eggs (SPAFAS; Charles River Labora-
tories, Wilmington, MA) were performed as described
[22]. Experiments were performed twice per treatment,
with 6 to 10 embryos per condition in every experiment.
Each CAM was locally treated with filter disks saturated
with a solution containing bFGF (50 ng/disk) and
VEGF121/ r G e l( 1o r1 0n M ) ,r G e l( 1o r1 0n M ) ,o rb u f -
fer (PBS). The filter was placed on the CAM in a region
with the lowest density of blood vessels and, as a refer-
ence, in the vicinity of a large vessel. Angiogenesis was
documented photographically 3 days after treatment;
images were captured using an Olympus stereomicro-
scope (SZ x12) and Spot Basic software (Diagnostic
Instruments, Inc.). The relative vascular density was
determined by measuring the area occupied by blood
vessels [23] using the public domain NIH Image
program (available on the Internet at http://rsb.info.nih.
gov/nih-image/). The numbers of blood vessel branch
points were independently and blindly quantified by two
researchers (C.G-M. and J.X.) and compared with the
numbers in the treatment controls [22].
RNA Extraction, Gene Expression Analysis, and RT-PCR
Correlative Analysis
HUVECs and PAE/VEGFR-2 cells were treated with
their respective IC50 VEGF121/rGel doses for 24 h. Con-
trol cells were treated with PBS. Total RNA was
extracted and analyzed for integrity as described [11].
HUVEC RNA was amplified and labeled using Cy3- and
Cy5-dCTP in the reverse transcription reaction. Dupli-
cate experiments were conducted by dye swapping. The
labeled samples were hybridized to a cDNA array of
2304 sequence-verified clones in duplicate printed by
the Cancer Genomics Core Laboratory (MDACC). The
array included 4800 genes involved in signal transduc-
tion, stress response, cell cycle control, hypoxia, and
metastatic spread. Differentially expressed genes were
identified on the basis of a cutoff value of the T value.
Generally, a cutoff value of |3| is considered statistically
significant. Genes that showed fold changes greater than
|2| in at least 3 of 4 arrays were identified, and the aver-
age fold change was determined. Microarray data were
verified by performing RT-PCR analysis on the genes
that showed the highest level of induction, namely E-
selectin (SELE), cytokine A2 (SCYA2, MCP-1), tumor
necrosis factor alpha induced protein 3 (TNFAIP3) and
NF-B inhibitor alpha (NF-BIa). Primers were
designed on the basis of the accession numbers from
the microarray and confirmation of homology using
BLAST (NCBI). Induction of E-selectin in PAE/VEGFR-
2 cells was also verified by RT-PCR. GAPDH primers
were used as controls.
Results
VEGF121/rGel binds to both VEGFR-1 and VEGFR-2
VEGF121 has been previously shown to bind to both
VEGFR-1 and VEGFR-2 with similar affinity [16]. Cells
over-expressing VEGFR-2 are nearly 600-fold more sen-
sitive to VEGF121/rGel than cells expressing VEGFR-1
[10] despite just a 3-fold higher receptor number on the
cell surface. We investigated the relative binding of
VEGF121/rGel to PAE cells expressing each of the recep-
tors. Expression of the two receptors was confirmed by
Western blot (Figure 1A). Total binding of
125I-
VEGF121/rGel to both PAE/VEGFR-1 and PAE/VEGFR-
2 cells was nearly identical and was effectively competed
by unlabeled VEGF121/rGel but not by unlabeled gelo-
nin, indicating that binding of VEGF121/rGel was
mediated by the VEGF121 component of the construct
and, therefore, the cytotoxic effects were VEGF
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sence of free gelonin seemed to slightly increase binding
of
125I-VEGF121/rGel to both cells. The reason for this
is unclear but may be due to gelonin blocking non-spe-
cific sites that may otherwise bind VEGF121/rGel.
VEGF121/rGel is internalized into PAE/VEGFR-2 cells but
not into PAE/VEGFR-1 cells
Because VEGF121/rGel appears to bind VEGFR-1, we
examined the role of internalization to explain the lack
of cytotoxicity of VEGF121/rGel on PAE/VEGFR-1 cells.
After incubation of cells with VEGF121/rGel, the cell
surface was stripped to probe only for internalized pro-
tein. VEGF121/rGel was detected in PAE/VEGFR-2 cells
within 1 hour of treatment with the immunofluores-
cence signal progressively increasing by 24 hours (Figure
1C). No VEGF121/rGel was detected in PAE/VEGFR-1
cells up to 24 hours after treatment with the fusion
toxin. Because no internalization is observed into PAE/
VEGFR-1 cells at both short and long time points, it is
unlikely that differences in receptor recycling rates, if
any, in the two receptor-transfected cells contribute to
these observations. Treatment of cells with the same
concentration of gelonin also showed no internalization
(see Additional file 1), confirming that entry of
VEGF121/rGel into PAE cells occurred almost exclu-
sively via VEGFR-2.
VEGF121/rGel cytotoxicity on endothelial cells correlates
with exposure time
Because VEGF121/rGel internalized into PAE/VEGFR-2
cells within one hour of incubation, we studied the cyto-
toxic effect of VEGF121/rGel as a function of exposure
time of this agent on endothelial cells. PAE/VEGFR-2
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Figure 1 VEGF121/rGel binds to both VEGFR-1 and VEGFR-2 but is cytotoxic only to VEGFR-2-expressing endothelial cells. A, Expression
of both receptors on their respective cell-lines was confirmed. B, Receptor-specific binding of radiolabeled VEGF121/rGel. Binding was reduced
with unlabeled VEGF121/rGel but not by unlabeled gelonin. C, VEGF121/rGel enters PAE/VEGFR-2 cells within one hour of treatment. However,
PAE/VEGFR-1 cells did not internalize VEGF121/rGel even after 24 hours of incubation with VEGF121/rGel. D, Effect of exposure time of VEGF121/
rGel on PAE/VEGFR-2 cells on cytotoxicity.
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and the cytotoxic effect was assessed at the end of the
72-hour period. VEGF121/rGel demonstrated targeted
toxicity even after a one-hour exposure, with an IC50 of
5 nM. The maximal cytotoxic effect of VEGF121/rGel on
PAE/VEGFR-2 cells was observed at 48 and 72 hours
(IC50 = 0.1 nM) (Figure 1D). The cytotoxic effect of
VEGF121/rGel on PAE/VEGFR-1 cells was similarly
affected as a function of exposure duration (see Addi-
tional file 2) in that longer exposure times resulted in
higher cytoxicity with the maximum cytotoxic effect
occurring at 72 h (IC50 = 100 nM).
VEGF121/rGel treatment activates VEGFR-2 downstream
signaling
Activation of downstream signaling by the receptor-
fusion protein complex may be necessary to facilitate
the internalization of the receptor/ligand complex, and
may also increase the susceptibility of the cell to the
toxic effects of rGel. We evaluated endogenous levels of
phosphorylated VEGFR-2 (p-VEGFR-2) in endothelial
cells that had been treated with VEGF121/rGel. PAE/
VEGFR-2 cells expressed levels of p-VEGFR-2 that
increased within 2 h after VEGF121/rGel treatment. The
levels of p-VEGFR-2 peaked at 4 h and gradually
decreased to endogenous levels by 24 h posttreatment
(Figure 2A, left panel). Endogenous levels of total
VEGFR-2 were also increased by 4 h and were reduced
to pretreatment levels by 24 h. In contrast, endogenous
levels of total VEGFR-2 in HUVECs decreased slightly
at 24 h after treatment with VEGF121/rGel, whereas p-
VEGFR-2 levels after 24 h were markedly upregulated
compared with the levels of untreated cells (Figure 2A,
right panel).
Positive Control           0 hr 48 hr
Negative Control          24 hr 72 hr
A
C
Full Length PARP
Cleaved PARP
Actin
VEGF121/rGel        - +      +      +       +       +       - - -
Dexamethasone   - - - - - -
0      0.5       2       4       24     48      24     24      24 
Treatment (h) PAE/VEGFR-2 HUVEC
NT  24 h         NT  24 h Antibody
anti-caspase-3
anti-Actin
anti-Bax
anti-Bcl-XL
B
D
Antigen
VEGFR-2
HUVEC
NT       24 h NT
30 min
2 h
4 h
24 h
48 h
PAE/VEGFR-2
p-VEGFR-2
Actin
Figure 2 Cytotoxicity of VEGF121/rGel to PAE/VEGFR-2 cells does not result in apoptosis. A, Decreased VEGFR-2 and increased p-VEGFR-2
levels in PAE/VEGFR-2 cells and HUVECs treated with VEGF121/rGel at IC50 doses for 24 h. Actin levels were used as a loading control. NT, not
treated. B, TUNEL analysis of PAE/VEGFR-2 cells treated with 1 nM VEGF121/rGel for 24, 48 and 72 hours. Positive control cells were incubated
with 1 mg/ml DNAse for 10 minutes at 37°C. C, Lack of effect of VEGF121/rGel on apoptotic markers in endothelial cells. Protein levels of Bax, Bcl-
XL and caspase-3 remained unchanged, suggesting that the mechanism of cell death induced by the construct is not apoptotic. Levels of
cytochrome C, caspase-6, and Bcl-2 were undetectable (data not shown). NT, not treated. D, PAE/VEGFR-2 cells treated with VEGF121/rGel did not
demonstrate PARP cleavage, while cells exposed to dexamethasone (positive control) showed cleaved PARP.
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Page 5 of 11Cytotoxic effects of VEGF121/rGel on endothelial cells are
not mediated via apoptotic mechanisms
Nuclei of positive control PAE/VEGFR-2 cells showed
intense TUNEL staining (Figure 2B). In contrast, no
TUNEL staining was observed with PAE/VEGFR-2 cells
exposed to VEGF121/rGel up to 72 hours, indicating that
the mechanism of cytotoxicity of VEGF121/rGel did not
involve apoptosis. To confirm this observation, we
examined various key apoptotic signaling events using
Western blot analysis. Levels of caspase-3 (full length
pre-cursor), Bax (a pro-apoptotic protein), and Bcl-XL
(an apoptosis inhibitor) were not found to be affected
by VEGF121/rGel treatment (Figure 2C). In addition, the
p11 and p20 subunits of activated/cleaved caspase-3
were not detected after treatment with the fusion con-
struct. Levels of the pro-apoptotic molecules cyto-
chrome C and caspase-6, as well as the anti-apoptotic
protein Bcl-2 were undetectable before or after treat-
ment (data not shown). PARP cleavage was tested on
PAE/VEGFR-2 cells by treating cells with VEGF121/rGel
or VEGF121 for periods ranging from 5 minutes to 48
hours. Western blot analysis of these cells by an anti-
PARP antibody showed that neither VEGF121/rGel nor
VEGF121 activated PARP-mediated apoptosis (Figure 2D;
VEGF121 data in Additional file 3).
VEGF121/rGel inhibits tube formation in VEGFR-2-
expressing endothelial cells
We next investigated the anti-angiogenic effect of
VEGF121/rGel on tube formation of endothelial cells
on Matrigel coated plates, a well established in vitro
assay for angiogenesis. The addition of 1 nM VEGF121/
rGel was found to significantly inhibit tube formation
in PAE/VEGFR-2 cells compared to untreated cells,
whereas rGel alone had little effect at this dose level
(Figure 3A). rGel alone caused ~42% inhibition at only
the highest concentration tested (100 nM). PAE/
VEGFR-1 cells were not as sensitive to VEGF121/rGel
as PAE/VEGFR-2 cells, requiring 100 nM VEGF121/
rGel or rGel to inhibit tube formation by 50% (Figure
3B). To determine whether pre-treatment of PAE/
VEGFR-2 cells with VEGF121/rGel affects tube forma-
tion, cells were treated with the IC50 dose of VEGF121/
rGel for 1 to 24 h, washed with PBS, detached, added
to Matrigel-coated plates in VEGF121/rGel-free med-
ium, and incubated for an additional 24 h. Prior incu-
bation of cells with VEGF121/rGel for 16 or 24 h was
found to virtually abolish the formation of tube struc-
tures (Figure 3C).
VEGF121/rGel inhibits angiogenesis in the CAM of chicken
embryos
We investigated the antiangiogenic effects of VEGF121/
rGel in vivo using a chicken chorioallantoic membrane
(CAM) model. The vascularized area in the CAMs
treated with bFGF was about 35% higher than in those
treated with PBS, the difference being highly significant
(P < 0.001; t-test, double-sided; Figure 4A and 4D). This
observation was consistent with the finding of more
than a 60% increase in the number of newly-sprouted
vessels in the bFGF-treated CAMs compared with the
PBS-treated CAMs (P < 0.001; t-test, double-sided;
Figure 4E). Incubation of CAMs with bFGF without or
with 10 nM rGel resulted in normal angiogenic activity
and the formation of an ordered neovasculature (Figure
4A and 4B) showing no impact of the rGel toxin. In
contrast, treatment with 1 or 10 nM VEGF121/rGel
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Figure 3 VEGF121/rGel mediates inhibition of tube formation in
PAE/VEGFR-2 cells. A, One nM VEGF121/rGel was sufficient to
inhibit tube formation by 50%, whereas the same degree of
inhibition was seen with rGel only at 100 nM. B, Up to 100 nM
VEGF121/rGel was needed to inhibit tube formation in PAE/VEGFR-1
cells, the same concentration as the untargeted gelonin toxin. C,
Time-dependent inhibition of tube formation of PAE/VEGFR-2 cells
by VEGF121/rGel. Incubation of PAE/VEGFR-2 cells with VEGF121/rGel
for as little as 9 h was sufficient to abolish the ability of these cells
to form tubes by 50%.
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ture (Figure 4C) with complete inhibition of bFGF-
stimulated angiogenesis (P < 0.001; t-test, double sided;
Figure 4D and 4E). Many of the treated CAMs also
appeared to be devoid of vessel infiltration. Interestingly,
the number of branching points in the VEGF121/rGel-
treated CAMs was similar to that in the PBS-treated
CAMs (P > 0.5; t-test, double-sided; Figure 4E), suggest-
ing that VEGF121/rGel mainly inhibits bFGF-mediated
formation of newly sprouting branches from pre-existing
vessels. As expected, the disks treated with bFGF in
combination with rGel (at 1 or 10 nM) consistently
showed extensive vascularization that was comparable to
that found in those treated with bFGF alone (P >0 . 5 ;
t-test, double-sided).
Microarray analysis of HUVECs treated indicates VEGF121/
rGel upregulates genes involved in inflammation,
chemotaxis and transcription regulation
To further explore the intracellular effects of VEGF121/
rGel and identify molecular pathways in endothelial
cells that may influence cell survival and rGel-mediated
toxicity, we treated HUVECs with saline or with an IC50
dose of VEGF121/rGel for 24 h. Rigorous microarray
analysis resulted in selection of only those differentially
expressed genes whose levels were elevated to at least 2
fold higher than the baseline values in repeated experi-
ments. On this basis, 22 genes were found to be upregu-
lated by treatment with VEGF121/rGel at 24 h (Table 1).
In addition to upregulating select genes known to be
induced by VEGF alone, treatment with VEGF121/rGel
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Figure 4 VEGF121/rGel mediates inhibition of angiogenesis in chicken embryo CAMs via reduction of the vascular area and number of
vascular branches. A, Vasculature of a CAM after stimulation with bFGF alone. B, rGel had no effect on angiogenic stimulation of bFGF at either
1 nM or 10 nM. C, 1 nM VEGF121/rGel in the presence of 50 ng of bFGF inhibited angiogenesis. D and E, Quantitative evaluation of VEGF121/rGel-
mediated inhibition of angiogenesis in the CAM model, normalized to CAMs treated with buffer (PBS; equal to 100%). D, VEGF121/rGel at both 1
and 10 nM decreased the vascular area. As expected, rGel alone had no effect. E, VEGF121/rGel decreased the number of newly sprouting vessels.
VEGF121/rGel at a concentration of 1 nM dramatically affected the formation of the neovasculature, completely inhibiting bFGF-mediated
stimulation of the neovasculature. As expected, rGel did not affect the number of newly sprouting vessels. Data shown represent the means ±
standard deviations from replicated experiments. *, P < 0.001; t-test, double-sided.
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Page 7 of 11upregulated genes involved in inflammation, chemotaxis
and transcription regulation. The genes with the highest
levels of expression from four gene classifications were
validated by RT-PCR analysis. When normalized for
GAPDH, all four of the other PCR products were
increased after treatment with VEGF121/rGel, thus vali-
dating the results observed in the original microarray
(Figure 5A).
Surprisingly, we did not observe E-selectin protein
expression in HUVECs in control and 24 h - treated
cells (data not shown). However, induction of E-selec-
tin mRNA was observed (see Additional file 4) suggest-
ing that the ribosomal machinery had been effectively
inhibited. Because PAE/VEGFR-2 cells have been used
as in vitro models for endothelial cells in the tumor
neovasculature, we investigated the effect of VEGF121/
r G e lo ng e n ei n d u c t i o na n dp r o t e i ne x p r e s s i o ni n
these cells. PAE/VEGFR-2 cells were treated with sal-
ine or the IC50 dose of VEGF121/rGel for up to 48 h.
PCR analysis for E-selectin confirmed the increase in
message within 2 h after treatment of cells with
VEGF121/rGel (Figure 5B). In addition, Western blot
analysis demonstrated a slight increase in E-selectin
protein expression, although the increase in cellular
protein levels was modest compared with the observed
increase in message, and was obvious only up to 4 h
after treatment (Figure 5C). MKP-1 RNA levels were
upregulated 2.7-fold in HUVECs (Table 1). Western
blots against MKP-1 and ERK2, previously shown to
be upregulated by MKP-1 in HUVECs following injury,
also showed no change in protein expression (see
Additional file 5).
Discussion
Tumor neovascularization is highly dependent upon
numerous cytokines and signaling events critical for the
growth and organization of the vascular tree. A number
of agents targeting tumor neovascularization and which
interfere with one or several steps in this robust process
have demonstrated significant clinical efficacy and have
received FDA approval [24]. These include agents which
block angiogenesis signaling events by inhibiting various
growth factor receptor kinases [25]; interfere with VEGF
physical interaction with its receptors such as anti-
VEGF antibodies (bevacizumab and ranibizumab) and
anti-receptor antibodies (IMC-1121B and DC101)
[26,27]; and strategies that trap growth factor ligands
(VEGF-Trap) [28]. These have all shown antitumor effi-
cacy alone and in combination with conventional antitu-
mor modalities [29,30].
Table 1 HUVEC genes that increase following treatment with VEGF121/rGel for 24 hours, compared to untreated cells
Gene
classification
Accession
Number
Symbol Gene Mean fold
change
Cell adhesion H39560 SELE E-selectin (endothelial adhesion molecule 1)
a 94.6
H07071 VCAM Vascular cell adhesion molecule 1 4.9
AA284668 PLAU Plasminogen activator, urokinase 2.3
Apoptosis AA476272 TNFAIP3 Tumor necrosis factor alpha-induced protein 3
a 13.5
H48706 BIRC3 baculoviral IAP repeat-containing 3 3.3
Transcription regulation T99236 JUNB jun B proto-oncogene 4.9
W55872 NF-BIa nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha
a 4.8
AA451716 NF-B1 nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105) 2.3
H45711 KLF4 Kruppel-like factor 4 2.3
Chemotaxis AA425102 SCYA2 small inducible cytokine A2 (MCP-1)
a 20.2
H62985 SCYA4 small inducible cytokine A4 (MIP-1b) 5.8
AA040170 SCYA7 small inducible cytokine A7 (MCP-3) 5.5
T62491 CXCR4 chemokine (C-X-C motif), receptor 4 (fusin) 1.85
Structural organization NM_004856 KNSL5 kinesin-like 5 (mitotic kinesin-like protein 1) 6.4
AA479199 NID2 nidogen 2 3.1
AA453105 H2AFL H2A histone family, member L 2.5
Inflammatory response W69211 SCYA11 small inducible cytokine A11 (Cys-Cys) 8.4
NM_001964 EGR1 (eotaxin) early growth response 1 3.9
NM_000963 PTGS2 prostaglandin-endoperoxide synthase 2 (COX-2) 3.3
AA148736 SCD4 syndecan 4 (amphiglycan, ryudocan) 3.2
Signaling W65461 DUSP5 dual specificity phosphatase 5 (MKP-1) 2.7
Metabolic AA011215 SAT spermidine/spermine N1-acetyltransferase 2.1
a Confirmed by RT-PCR at 4 and 24 h posttreatment
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Page 8 of 11VEGF-A has been shown to play an important role in
tube formation of endothelial cells in vitro [31] and in
angiogenesis [32]. In the present study, the effect of
VEGF121/rGel on tube formation of endothelial cells on
Matrigel-coated plates was striking in that cells overex-
pressing VEGFR-2, but not cells overexpressing VEGFR-
1, were affected. This result is consistent with our find-
ings that VEGF121/rGel is cytotoxic only to VEGFR-2-
expressing endothelial cells [10] and is internalized only
into endothelial cells that express VEGFR-2 but not
VEGFR-1 (this study). The inhibition by VEGF121/rGel
of tube formation in vitro translates well to inhibition of
both vascular endothelial growth and neovasculature in
vivo in the CAM membrane assays. The CAM assay
also demonstrated that treatment with VEGF121/rGel
did not affect mature vessels. This critical finding sup-
ports our hypothesis that VEGF121/rGel does not affect
mature vessels in either normal tissues or tumors since
both VEGFR-1 and VEGFR-2 are over-expressed on the
endothelium of tumor neovasculature [33-36] but are
almost undetectable in the vascular endothelium of adja-
cent normal tissues and in mature tumor vessels. There-
fore, small, newly vascularizing tumors and metastases
may be the lesions most responsive to therapy with this
agent.
The lack of internalization of VEGF121/rGel into PAE/
VEGFR-1 cells explains the difference in cytotoxicity
compared to PAE/VEGFR-2. This also supports the
hypothesis that VEGFR-1 is a decoy receptor, at least on
endothelial cells, as it demonstrates weak tyrosine phos-
phorylation upon VEGF stimulation [34]. However, we
have demonstrated that mouse monocytes internalize
VEGF121/rGel via VEGFR-1 [12], suggesting that other
factors may influence VEGFR-1 receptor activity such as
cell type, total receptor number and dimerization partner.
While the mechanism of rGel itself is to target the
ribosomal machinery, the extent to which translation
is inhibited will affect downstream cellular responses,
such as other mechanisms of cell death. Information
about these mechanisms may reveal additional path-
ways that can be targeted in combination with the
fusion toxin to achieve optimal efficacy. Our study
demonstrates that the cytotoxic effect of VEGF121/
rGel on VEGFR-2-overexpressing endothelial cells is
not due to programmed cell death (apoptosis). Pre-
vious studies of a gelonin-based immunotoxin target-
ing tumor cells showed that intoxicated cells did not
appear to display apoptotic characteristics [37]. In
contrast, gelonin coupled to BlyS induced apoptosis
in B cells [38] strongly supporting the idea that cell
GAPDH
TNFAIP3
NF-țBIĮ
SCYA2
NT    24 h
E-selectin
AB
GAPDH
E-selectin
NT
C
anti-actin
anti-E-selectin
NT
Figure 5 Microarray and protein expression analysis of endothelial cells treated with VEGF121/rGel. A, Validation of the microarray analysis
by PCR is shown. Upregulation of genes for E-selectin, TNFAIP3, NF-BIa and SCYA2 were validated by RT-PCR. GAPDH levels were assessed as a
control. B, RNA from PAE/VEGFR-2 cells untreated or treated with VEGF121/rGel for the periods indicated were examined by PCR for upregulation
of E-selectin. GAPDH primers were used as a control for loading. RNA levels of E-selectin were all upregulated in PAE/VEGFR-2 cells, as well as in
HUVECs. C, Protein levels of E-selectin are only slightly upregulated compared to E-selectin RNA.
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Page 9 of 11type differences can affect the mechanism of
cytotoxicity.
A critical finding of this study is the identification of
several genes that are regulated in response to treatment
with the VEGF121/rGel fusion construct. We observed
an increase in the RNA levels of several genes that are
involved in inflammation, chemotaxis, intermediary
metabolism, and apoptotic pathways (Table 1). To our
knowledge, this microarray analysis is the first to be per-
formed on cells treated with a gelonin-based therapeu-
tic. A previous report showed that only two of these
genes, MKP-1 and CXCR4, were also upregulated in
HUVECs after treatment with VEGF165 for 24 h [17].
The present study shows that VEGF121/rGel is a mem-
ber of the class of molecules that can prevent E-selec-
tin-mediated metastasis because protein levels barely
doubled in both PAE/VEGFR-2 and HUVECs after
treatment with VEGF121/rGel. We observed a similar
pattern of induction of RNA but not protein levels with
other genes as well. Several genes involved in the con-
trol of the apoptotic pathway were modulated in
response to the fusion toxin even though the overall
cytotoxic effect on target cells did not include an obser-
vable impact on the apoptotic pathway. Taken together,
we conclude VEGF121/rGel induces an increase in
mRNA levels of genes that are important in cell adhe-
sion, migration, and inflammatory response but gener-
ally does not induce a concomitant increase in protein
expression. Since the rGel component of the fusion con-
struct operates by inhibiting protein synthesis, VEGF121/
rGel could inhibit synthesis of critical proteins that are
important for suppression of these specific genes. In our
laboratory, current studies are under way in breast and
prostate orthotopic and metastatic (i.e., lung and bone)
tumor models to further characterize the effects of this
drug in vitro and in vivo.
Conclusions
Our study shows that the specific cytotoxic effect of
VEGF121/rGel observed against tumor vasculature in
vivo is due to targeting of endothelial cells that overex-
press VEGFR-2. VEGF121/rGel is rapidly internalized
into log-phase endothelial cells via VEGFR-2 and
mediates a robust cytotoxic effect that is primarily
necrotic and negates the upregulation of genes
involved in inflammation, chemotaxis and transcription
regulation. However, modulation of these genes may
influence tumor development in addition to exerting
direct cytotoxic effects on the tumor neovasculature.
Therefore, important considerations for future study
are the effects of VEGF121/rGel cytotoxicity on tumor
endothelial cells and the potential bystander effects
of the construct on adjacent cells in the tumor
microenvironment.
Additional material
Additional File 1: At an equivalent molar concentration as VEGF121/
rGel (48 nM), no internalization of recombinant gelonin (rGel) was
detected in PAE/VEGFR-2 or PAE/VEGFR-1 cells over 24 h.
Additional File 2: As with PAE/VEGFR-2 cells, cytotoxicity of VEGF121/
rGel on PAE/VEGFR-1 cells is dependent on exposure time, but
overall cytotoxicity is significantly lower. rGel exposure time is 72 h.
Additional File 3: Treatment of PAE/VEGFR-2 cells with VEGF121 or
VEGF121/rGel does not result in PARP cleavage.
Additional File 4: Upregulation of E-Selectin in HUVECs over 24 h
after treatment with VEGF121/rGel, as determined by PCR analysis.
GAPDH was used as a control for loading.
Additional File 5: MKP-1 protein expression did not correspond to a
2.7-fold increase in RNA levels in HUVECs over 24 h. ERK-2 protein
expression, previously shown to be regulated by MKP-1 in HUVECs, also
showed no change in protein expression.
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